Pages

2013/08/24

iQUOTE

"Vedolizumab has clinical promise as a potential treatment option for people with moderate to severely active Crohn's and UC," said Paul Rutgeerts M.D., Ph.D., of the Catholic University of Leuven in Belgium."While there is no known cure, there is a need for new CD and UC treatment options, in an effort to provide patients with additional choices for managing their disease, reducing symptoms and achieving remission," he added.


Source: Sandborn W, Feagan B, Rutgeerts P, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2013;369;8:711-721.

#DemocracygoOut!